Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biolase (DE:BTH0)
FRANKFURT:BTH0
Biolase (BTH0) Stock Price & Analysis
1 Followers
BTH0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.01 - €10.70
Previous Close€0.01
Volume0.00
Average Volume (3M)2.71K
Market Cap
€2.33M
Enterprise ValueN/A
Total Cash (Recent Filing)$6.50M
Total Debt (Recent Filing)$15.33M
Price to Earnings (P/E)―
Beta-54.84
Next Earnings
Aug 08, 2024EPS Estimate
-€0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,040,000
10 Day Avg. Volume25
30 Day Avg. Volume2,715
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.20
Price to Sales (P/S)0.00500
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
€3.27Price Target Upside32563.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Biolase News
PremiumCompany Announcements
Biolase Announces Common Stock Shares Update
PremiumCompany Announcements
Biolase Raises $7 Million, Expands Capital and Ensures Compliance
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement maintained 2024 guidance for revenue of $52 – 53 million (+6 – 8%) and expects to achieve positive adjusted EBITDA for the full year of 2024.
Market ExpansionBIOLASE continues to make progress in expanding to Dental Services Organizations (DSOs) and is expanding its various marketing programs especially to dental specialists.
Product DevelopmentThe launch of the Waterlase iPlus Premier Edition provides a more accessible price point, potentially boosting future sales.
Bears Say
Capital Raise And Stock DilutionBased on BIOL’s cash position and the analyst's financial forecasts, the company will need to execute a potentially dilutive capital raise before the end of 2024, which is expected to further suppress BIOL’s common stock.
RevenueRevenue was down due to a weaker macro environment causing delays in sales.
Workforce And Cost CutsBIOLASE initiated cost cuts reducing its U.S. workforce by approximately 15%, resulting in projected annualized cost savings of around $2.5 million. This is on top of layoffs of around 20% in June 2023.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.49% Other Institutional Investors
99.51% Public Companies and
Individual Investors
BTH0 FAQ
What was Biolase’s price range in the past 12 months?
Biolase lowest stock price was €0.01 and its highest was €10.70 in the past 12 months.
What is Biolase’s market cap?
Currently, no data Available
When is Biolase’s upcoming earnings report date?
Biolase’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Biolase’s earnings last quarter?
Biolase released its earnings results on May 13, 2024. The company reported -€0.335 earnings per share for the quarter, missing the consensus estimate of -€0.158 by -€0.177.
Is Biolase overvalued?
According to Wall Street analysts Biolase’s price is currently Undervalued.
Does Biolase pay dividends?
Biolase does not currently pay dividends.
What is Biolase’s EPS estimate?
Biolase’s EPS estimate is -€0.07.
How many shares outstanding does Biolase have?
Currently, no data Available
What happened to Biolase’s price movement after its last earnings report?
Biolase reported an EPS of -€0.335 in its last earnings report, missing expectations of -€0.158. Following the earnings report the stock price went down -0.709%.
Which hedge fund is a major shareholder of Biolase?
Currently, no hedge funds are holding shares in DE:BTH0
---
Biolase Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.05%
12-Months-Change
Fundamentals
Return on Equity
-683.42%
Trailing 12-Months
Asset Growth
-18.10%
Trailing 12-Months
Company Description
Biolase
BIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
---
BTH0 Earnings Call
Q1 2024
0:00 / 0:00
---
BTH0 Stock 12 Month Forecast
Average Price Target
€3.27
▲(32563.40% Upside)
Technical Analysis
Best Analysts Covering BTH0
1 Year
1 Year Success Rate
1/14 ratings generated profit
1 Year Average Return
-71.34%
reiterated a buy rating 2 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -71.34% per trade.
---